2-Thiocytidine

TargetMol
Product Code: TAR-TNU0436
Supplier: TargetMol
CodeSizePrice
TAR-TNU0436-1mg1mg£96.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TNU0436-5mg5mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TNU0436-10mg10mg£146.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TNU0436-25mg25mg£193.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TNU0436-50mg50mg£251.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TNU0436-100mg100mg£344.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TNU0436-500mg500mg£707.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TNU0436-1g1g£962.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20°C

Images

1 / 1

Further Information

Bioactivity:
2-Thiocytidine is a purine nucleoside analog that targets malignant tumors of the inert lymphatic system and has a broad spectrum of antitumor activity.2-Thiocytidine induces apoptosis by inhibiting DNA synthesis.2-Thiocytidine is a purine nucleoside analog that targets malignant tumors of the inert lymphatic system.
CAS:
13239-97-9
Formula:
C9H13N3O4S
Molecular Weight:
259.28
Pathway:
Cell Cycle/Checkpoint|Apoptosis|DNA Damage/DNA Repair
Purity:
0.98
SMILES:
O[C@H]1[C@@H](O[C@H](CO)[C@H]1O)N2C(=S)N=C(N)C=C2
Target:
DNA/RNA Synthesis|Apoptosis|Nucleoside Antimetabolite/Analog

References

Vangaveti S, et al. A Structural Basis for Restricted Codon Recognition Mediated by 2-thiocytidine in tRNA Containing a Wobble Position Inosine. J Mol Biol. 2020;432(4):913-929. Robak T, et al. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-3388.